These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6849518)

  • 21. [The autoantibody profile and disease activity in patients with systemic lupus erythematosus].
    Horák P; Hermanová Z; Faltýnek L; Pospísil Z; Scudla V
    Vnitr Lek; 1997 Oct; 43(10):639-44. PubMed ID: 9601876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome.
    Inanç M; Donohoe S; Ravirajan CT; Radway-Bright EL; Mackie I; Machin S; Isenberg DA
    Br J Rheumatol; 1998 Oct; 37(10):1089-94. PubMed ID: 9825748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
    Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
    Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus.
    Lee JH; Wang LC; Lin YT; Yang YH; Lin DT; Chiang BL
    Immunology; 2006 Feb; 117(2):280-6. PubMed ID: 16423064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus.
    Linker-Israeli M; Hyun S; Ozeri-Chen T; Wallace DJ; Banks K; Klinenberg JR
    J Immunol; 1994 Mar; 152(6):3158-67. PubMed ID: 8144910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Soluble CD40 ligand in systemic lupus erythematosus and antiphospholipid syndrome].
    Aleksandrova EN; Novikov AA; Popkova TV; Reshetniak TM; Novikova DS; Kliukvina NG; Il'ina AE; Mach ES; Volkov AV; Nasonov EL
    Ter Arkh; 2006; 78(6):35-9. PubMed ID: 16881361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
    Svenungsson E; Gunnarsson I; Fei GZ; Lundberg IE; Klareskog L; Frostegård J
    Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical usefulness of antibodies to U1snRNP proteins in mixed connective tissue disease and systemic lupus erythematosus.
    Margaux J; Hayem G; Palazzo E; Chazerain P; De Bandt M; Haim T; Kahn MF; Meyer O
    Rev Rhum Engl Ed; 1998 Jun; 65(6):378-86. PubMed ID: 9670329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
    Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Xu D; Roschke V; Wu Y; Baker KP; Hilbert DM
    Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
    Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus.
    Reichlin M; Fesmire J; Quintero-Del-Rio AI; Wolfson-Reichlin M
    Arthritis Rheum; 2002 Nov; 46(11):2957-63. PubMed ID: 12428237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
    Papadimitraki ED; Choulaki C; Koutala E; Bertsias G; Tsatsanis C; Gergianaki I; Raptopoulou A; Kritikos HD; Mamalaki C; Sidiropoulos P; Boumpas DT
    Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An immunohistochemical study of IgE in the skin of patients with systemic lupus erythematosus (author's transl)].
    Igarashi R
    Nihon Hifuka Gakkai Zasshi; 1975 Jun; 85(7):385-93. PubMed ID: 1081155
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of antinuclear antibody and other immunohematological profiles among primary Sjögren's syndrome, secondary Sjögren's syndrome associated with rheumatoid arthritis or systemic lupus erythematosus, and corresponding systemic disease.
    Ichikawa Y; Takaya M; Shimizu H; Uchiyama M; Moriuchi J; Morita K; Hoshina Y; Horiki T
    Tokai J Exp Clin Med; 1993 Dec; 18(3-6):133-8. PubMed ID: 7701526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
    Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
    Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
    Mak A; Cheung BM; Mok CC; Leung R; Lau CS
    Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
    Zandman-Goddard G; Blank M; Langevitz P; Slutsky L; Pras M; Levy Y; Shovman O; Witte T; Doria A; Rovensky J; Shoenfeld Y
    Ann Rheum Dis; 2005 Dec; 64(12):1698-702. PubMed ID: 16014675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
    Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
    Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.
    Liu CC; Manzi S; Kao AH; Navratil JS; Ruffing MJ; Ahearn JM
    Arthritis Rheum; 2005 Oct; 52(10):3087-99. PubMed ID: 16200588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.